Etoposide Aeon

Etoposide Aeon may be available in the countries listed below.

Ingredient matches for Etoposide Aeon

Etoposide

Etoposide is reported as an ingredient of Etoposide Aeon in the following countries:

• Greece

International Drug Name Search

Factive

Factive is a brand name of gemifloxacin, approved by the FDA in the following formulation(s):

FACTIVE (gemifloxacin mesylate - tablet; oral)

• 
  Manufacturer: CORNERSTONE THERAP
  
  Approval date: April 4, 2003
  
  Strength(s): EQ 320MG BASE ^[RLD]

Has a generic version of Factive been approved?

No. There is currently no therapeutically equivalent version of Factive available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Factive. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituent and processes for preparing thereof
  Patent 5,633,262
  Issued: May 27, 1997
  Inventor(s): Hong; Chang Y. & Kim; Young K. & Chang; Jay H. & Kim; Se H. & Choi; Hoon & Nam; Do H. & Kwak; Jin H. & Jeong; Yi N. & Oh; Jeong I. & Kim; Mu Y.
  Assignee(s): LG Chemical Ltd.
  The present invention relates to a novel quinolone compound having an excellent antibacterial activity. More specifically, the present invention relates to a novel quinoline(naphthyridine)carboxylic acid derivative represented by the following formula (I), which has an 4-aminomethyl-3-oximepyrrolidine substituent on 7-position of the quinolone nucleus and shows a superior antibacterial activity in contrast to the known quinolone antibacterial agents having a weak activity against gram-positive bacterial strains and also has a broad antibacterial spectrum and a highly improved pharmacokinetic property: ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and Q are defined as described in the specification.
  
  Patent expiration dates:
  
  
  • June 15, 2015
    
  
  



• 
  7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof
  Patent 5,776,944
  Issued: July 7, 1998
  Inventor(s): Hong; Chang Yong & Kim; Young Kwan & Kim; Se Ho & Chang; Jay Hyok & Choi; Hoon & Nam; Do Hyun & Kim; Ae Ri & Lee; Jin Hwa & Park; Ki Sook
  Assignee(s): LG Chemical Ltd.
  The present invention relates to a novel quinolone compound having an excellent antibacterial activity. More specifically, the present invention relates to 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4 -oxo-1, 4-dihydro-1,8-naphthyridine-3-carboxylic acid represent by the following formula: ##STR1## or its isomer.
  
  Patent expiration dates:
  
  
  • April 4, 2017
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1- cyclopropyl-6-fluoro-4-oxo-1, 4-dihydro-1, 8-naphthyridine-3-carboxylic acid and the process for the preparation thereof
  Patent 5,962,468
  Issued: October 5, 1999
  Inventor(s): Hong; Chang Yong & Kim; Young Kwan & Kim; Se Ho & Chang; Jay Hyok & Choi; Hoon & Nam; Do Hyun & Kim; Ae Ri & Lee; Jin Hwa & Park; Ki Sook
  Assignee(s): LG Chemical Ltd.
  The present invention relates to a novel quinolone compound having an excellent antibacterial activity. More specifically, the present invention relates to 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4 -oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid represent by the following formula: ##STR1## or its isomer.
  
  Patent expiration dates:
  
  
  • June 15, 2015
    
    ✓ 
    Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
  
  



• 
  Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria
  Patent 6,262,071
  Issued: July 17, 2001
  Inventor(s): Crabb; Donna M. & Duffy; Lynn B. & Searcy; Karen B.
  Assignee(s): SmithKline Beecham Corporation
  This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria.
  
  Patent expiration dates:
  
  
  • September 21, 2019
    
    ✓ 
    Patent use: METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA
  
  



• 
  Methods of use of quinolone compounds against anaerobic pathogenic bacteria
  Patent 6,331,550
  Issued: December 18, 2001
  Inventor(s): Citron; Diane M. & Goldstein; Ellie J. C.
  Assignee(s): SmithKline Beecham Corporation
  This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against pathogenic bacteria, especially anaerobic pathogens.
  
  Patent expiration dates:
  
  
  • September 21, 2019
    
    ✓ 
    Patent use: USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
  
  



• 
  Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
  Patent 6,340,689
  Issued: January 22, 2002
  Inventor(s): Jacques; Dubois & Claude; St-Pierre
  Assignee(s): SmithKline Beecham Corporation
  A method of treating an atypical upper respiratory pathogenic bacteria comprising administering a gemifloxacin compound is disclosed.
  
  Patent expiration dates:
  
  
  • September 14, 2019
    
    ✓ 
    Patent use: USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
  
  



• 
  Methods of use of quinolone compounds against anaerobic pathogenic bacteria
  Patent 6,455,540
  Issued: September 24, 2002
  Inventor(s): Diane M.; Citron & Ellie J. C.; Goldstein
  Assignee(s): SmithKline Beecham Corporation
  This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against pathogenic bacteria, especially anaerobic pathogens.
  
  Patent expiration dates:
  
  
  • September 21, 2019
    
    ✓ 
    Patent use: USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
  
  



• 
  Salt of naphthyridine carboxylic acid derivative
  Patent 6,723,734
  Issued: April 20, 2004
  Inventor(s): Ae Ri; Kim & Jin Hwa; Lee & Ki Sook; Park & Jong Ryoo; Choi & Tae Hee; Lee & Jay Hyok; Chang & Do Hyun; Nam & Hoon; Choi
  Assignee(s): LG Life Sciences, Ltd.
  7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.
  
  Patent expiration dates:
  
  
  • March 20, 2018
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Method of use of quinolone compounds against pneumococcal and haemophilus bacteria
  Patent 6,803,376
  Issued: October 12, 2004
  Inventor(s): Peter C.; Appelbaum & Kim L.; Credito & Todd; Davies & Diane B.; Hoellman & Linda M.; Kelly & Glenn A.; Pankuch
  Assignee(s): SmithKline Beecham Corporation
  This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria, particularly quinolone resistant S. pnemoniae and rare H. influenzae strains.
  
  Patent expiration dates:
  
  
  • September 21, 2019
    
    ✓ 
    Patent use: USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 21, 2019
    
    ✓ 
    Patent use: USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Factive Consumer Information (Wolters Kluwer)
• Factive Consumer Information (Cerner Multum)
• Factive Advanced Consumer Information (Micromedex)
• Factive AHFS DI Monographs (ASHP)
• Gemifloxacin Consumer Information (Wolters Kluwer)
• Gemifloxacin Consumer Information (Cerner Multum)
• Gemifloxacin Advanced Consumer Information (Micromedex)
• Gemifloxacin Mesylate AHFS DI Monographs (ASHP)

Imipem

Imipem may be available in the countries listed below.

Ingredient matches for Imipem

Cilastatin

Cilastatin sodium salt (a derivative of Cilastatin) is reported as an ingredient of Imipem in the following countries:

• Italy

Imipenem

Imipenem monohydrate (a derivative of Imipenem) is reported as an ingredient of Imipem in the following countries:

• Italy

International Drug Name Search

Floksid

Floksid may be available in the countries listed below.

Ingredient matches for Floksid

Ciprofloxacin

Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Floksid in the following countries:

• Indonesia

International Drug Name Search

Digoxin Immune Fab

Pronunciation: di-JOX-in
Generic Name: Digoxin Immune Fab
Brand Name: Digibind and DigiFab

Digoxin Immune Fab is used for:

Treating severe, possibly life-threatening digoxin or digitoxin overdose.

Digoxin Immune Fab is an antidote for digoxin toxicity. It works by binding to digoxin and preventing it from working in the body.

Do NOT use Digoxin Immune Fab if:

• you are allergic to any ingredient in Digoxin Immune Fab

Contact your doctor or health care provider right away if any of these apply to you.

Before using Digoxin Immune Fab:

Some medical conditions may interact with Digoxin Immune Fab. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you are allergic to antibiotics, papain, chymopapain, or papaya extracts


• if you have previously received any medicines made from sheep


• if you have kidney problems, heart problems (eg, heart failure, atrial fibrillation), or abnormal blood potassium levels

Some MEDICINES MAY INTERACT with Digoxin Immune Fab. However, no specific interactions with Digoxin Immune Fab are known at this time.

This may not be a complete list of all interactions that may occur. Ask your health care provider if Digoxin Immune Fab may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Digoxin Immune Fab:

Use Digoxin Immune Fab as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Digoxin Immune Fab is given as an injection at your doctor's office, hospital, or clinic.


• If you miss a dose of Digoxin Immune Fab, contact your doctor right away.

Ask your health care provider any questions you may have about how to use Digoxin Immune Fab.

Important safety information:

• Digoxin Immune Fab may interfere with certain lab tests, including blood digitalis levels. Be sure your doctor and lab personnel know you are using Digoxin Immune Fab.


• LAB TESTS, including blood digoxin, digitoxin, or potassium levels, may be performed while you use Digoxin Immune Fab. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Use Digoxin Immune Fab with caution in the ELDERLY; they may be more sensitive to its effects.


• PREGNANCY and BREAST-FEEDING: It is not known if Digoxin Immune Fab can cause harm to the fetus. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Digoxin Immune Fab while you are pregnant. It is not known if Digoxin Immune Fab is found in breast milk. If you are or will be breast-feeding while you use Digoxin Immune Fab, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Digoxin Immune Fab:

All medicines may cause side effects, but many people have no, or minor, side effects. No COMMON side effects have been reported with Digoxin Immune Fab. Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); fast or irregular heartbeat; fever.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Digoxin Immune Fab side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.

Proper storage of Digoxin Immune Fab:

Digoxin Immune Fab is usually handled and stored by a health care provider. If you are using Digoxin Immune Fab at home, store Digoxin Immune Fab as directed by your pharmacist or health care provider. Keep Digoxin Immune Fab out of the reach of children and away from pets.

General information:

• If you have any questions about Digoxin Immune Fab, please talk with your doctor, pharmacist, or other health care provider.


• Digoxin Immune Fab is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Digoxin Immune Fab. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Digoxin Immune Fab resources

• Digoxin Immune Fab Side Effects (in more detail)
• Digoxin Immune Fab Use in Pregnancy & Breastfeeding
• Digoxin Immune Fab Drug Interactions
• Digoxin Immune Fab Support Group
• 0 Reviews for Digoxin Immune Fab - Add your own review/rating

• Digibind Prescribing Information (FDA)


• Digifab Prescribing Information (FDA)


• digoxin immune FAB Concise Consumer Information (Cerner Multum)

Compare Digoxin Immune Fab with other medications

• Digitalis Glycoside Toxicity

Streptomycin Pharmadrug

Streptomycin Pharmadrug may be available in the countries listed below.

Ingredient matches for Streptomycin Pharmadrug

Streptomycin

Streptomycin is reported as an ingredient of Streptomycin Pharmadrug in the following countries:

• Tunisia

International Drug Name Search

Erythrotrop

Erythrotrop may be available in the countries listed below.

Ingredient matches for Erythrotrop

Erythromycin

Erythromycin estolate (a derivative of Erythromycin) is reported as an ingredient of Erythrotrop in the following countries:

• Hungary

International Drug Name Search

Larylin Husten-Löser

Larylin Husten-Löser may be available in the countries listed below.

Ingredient matches for Larylin Husten-Löser

Ambroxol

Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Larylin Husten-Löser in the following countries:

• Germany

International Drug Name Search

Cefotron

Cefotron may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Cefotron

Cefoperazone

Cefoperazone is reported as an ingredient of Cefotron in the following countries:

• Portugal

International Drug Name Search

Exuna

Exuna may be available in the countries listed below.

Ingredient matches for Exuna

Algestone Acetophenide

Algestone Acetophenide is reported as an ingredient of Exuna in the following countries:

• Peru

Estradiol

Estradiol 17ß-enantate (a derivative of Estradiol) is reported as an ingredient of Exuna in the following countries:

• Peru

International Drug Name Search